An Open-Label Phase I/II, Pilot, Staggered Four-Cohort Safety and Proof-of-Concept Study of ApoGraft in the Prevention of Acute Graft Versus Host Disease (aGvHD)
Phase of Trial: Phase I/II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Mobilised-peripheral-blood-cells (Primary)
- Indications Haematological malignancies
- Focus Adverse reactions; Proof of concept
- Sponsors Cellect Biotechnology
- 27 Mar 2017 According to a Cellect Biotechnology media release, the first stem cell transplant procedure has been successfully performed using its ApoGraft technology in this trial.
- 23 Mar 2017 According to a Cellect Biotechnology media release, the first patient has been treated in this trial.
- 02 Mar 2017 New trial record